Prevention and management of tuberculosis in solid organ transplantation: A consensus statement of the transplantation society of Taiwan

J Formos Med Assoc. 2023 Oct;122(10):976-985. doi: 10.1016/j.jfma.2023.04.025. Epub 2023 May 13.

Abstract

Solid organ transplant recipients have an increased risk of tuberculosis (TB). Due to the use of immunosuppressants, the incidence of TB among solid organ transplant recipients has been consistently reported to be higher than that among the general population. TB frequently develops within the first year after transplantation when a high level of immunosuppression is maintained. Extrapulmonary TB and disseminated TB account for a substantial proportion of TB among solid organ transplant recipients. Treatment of TB among recipients is complicated by the drug-drug interactions between anti-TB drugs and immunosuppressants. TB is associated with an increased risk of graft rejection, graft failure and mortality. Detection and management of latent TB infection among solid organ transplant candidates and recipients have been recommended. However, strategy to mitigate the risk of TB among solid organ transplant recipients has not yet been established in Taiwan. To address the challenges of TB among solid organ transplant recipients, a working group of the Transplantation Society of Taiwan was established. The working group searched literatures on TB among solid organ transplant recipients as well as guidelines and recommendations, and proposed interventions to strengthen TB prevention and care among solid organ transplant recipients.

Keywords: Candidate; Recipient; Solid organ; Transplant; Tuberculosis.

Publication types

  • Practice Guideline

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Organ Transplantation* / adverse effects
  • Taiwan / epidemiology
  • Tuberculosis* / diagnosis
  • Tuberculosis* / drug therapy
  • Tuberculosis* / epidemiology

Substances

  • Antitubercular Agents
  • Immunosuppressive Agents